Santen Pharmaceutical

Update in progress

4536.T (Tokyo)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Santen Pharmaceutical Co., Ltd. develops, manufactures, and markets medicines and medical devices for eye diseases worldwide, including Japan, China, Asia, Europe, the Middle East, Africa, and beyond. Its portfolio includes tafluprost/timolol and latanoprost for glaucoma and ocular hypertension, ciclosporin for allergic conjunctivitis, epinastine, and a range of other ophthalmic products such as netarsudil/latanoprost, sepetaprost, and omidenepag isopropyl. The company is based in Osaka and was founded in 1890.

Company score

Sentiment: 0.29; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.09; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive